ABBV ABBV アッヴィABBVのチャート
ABBVの企業情報
| symbol | ABBV |
|---|---|
| 会社名 | AbbVie Inc （ABBV アッヴィ） |
| 分野（sector） | |
| 産業（industry） | |
| 業種 | 医薬品 医療関連（Health Care） |
| 概要 | 事業概要 アッヴィ(AbbVie Inc.)は研究型バイオ医薬品会社である。同社は各種医薬品の発見・開発・製造・販売に従事する。同社の製品はリウマチ学、胃腸病学と皮膚科学等の慢性自己免疫疾患、血液癌を含む腫瘍学、C型肝炎ウイルス（HCV）とヒト免疫不全ウイルス（HIV）を含むウイルス学、パーキンソン病と多発性硬化症等の神経学的障害、甲状腺疾患と嚢胞性線維症関連合併症を含む代謝性疾患、並びに他の健康状態の治療のために使用される。同社はHUMIRA（アダリムマブ）、腫瘍学製品、ウイルス学、追加のウイルス学製品、代謝またはホルモン製品、内分泌学製品、並びにDuopaおよびDuodopa（カルビドパおよびレボドパ）、麻酔薬およびZINBRYTA（ダクリズマブ）を含む他の製品を提供する。 アッヴィは米国の研究開発型バイオ医薬品企業。主にC型肝炎、神経学、免疫学、腫瘍学、慢性腎疾患および女性の疾患などの分野における医薬品の開発に取り組む。アボット・ラボラトリ―ズの研究開発医薬品部門の分離独立に伴い2013年度に設立。主力製品はリウマチ性関節炎や乾癬治療薬｢ヒュミラ｣など。本社はイリノイ州ノ―ス・シカゴ。 at abbvie, we believe the world needs new approaches to addressing today’s health issues — from life-threatening illness to chronic conditions. we combine advanced science, expertise and passion to solve serious health issues and have a remarkable impact on people’s lives. with 28,000+ employees and medicines in over 170 countries, abbvie is uniting the best of pharma and the boldness of biotech, to innovate end-to-end approaches that make a real difference in people’s lives. for more information visit www.abbvie.com review our linkedin community guidelines at http://bit.ly/abbviesocialguidelines |
| 本社所在地 | 847 932-7900 |
| 代表者氏名 | Richard A. Gonzalez |
| 代表者役職名 | Chairman of the Board Chief Executive Officer |
| 電話番号 | +1 847-932-7900 |
| 設立年月日 | 41000 |
| 市場名 | NYSE（ニューヨーク証券取引所） |
| ipoyear | 年 |
| 従業員数 | 30000人 |
| url | www.abbvie.com |
| nasdaq_url | |
| adr_tso | |
| EBITDA | EBITDA（百万ドル） 9148.00000 |
| 終値（lastsale） | |
| 時価総額（marketcap） | |
| 時価総額 | 時価総額（百万ドル） 119125.30000 |
| 売上高 | 売上高（百万ドル） 32753.00000 |
| 企業価値(EV) | 企業価値(EV)（百万ドル） 151374.30000 |
| 当期純利益 | 当期純利益（百万ドル） 5743.00000 |
| 決算概要 | 決算概要 BRIEF: For the fiscal year ended 31 December 2018 AbbVie Inc revenues increased 16% to $32.75B. Net income applicable to common stockholders excluding extraordinary items increased 1% to $5.74B. Revenues reflect an increase in demand for the Company's products and services due to favorable market conditions. Net income was partially offset by Research and development - Balanci increase from $4.82B to $10.16B (expense) Selling. |
ABBVのテクニカル分析
ABBVのニュース
Pharmaceutical Giant Merck Challenges Inflation Reduction Act over Medicare Drug Pricing, Calls It ''Extortion'' 2023/06/06 19:03:23 Benzinga
Merck & Co Inc (NYSE: MRK ) has reportedly filed a lawsuit against the U.S. government to halt implementing the Medicare drug price negotiation program outlined in the Inflation Reduction Act (IRA). Pfizer Inc''s (NYSE: PFE ) CEO Albert Bourla called U.S. plans to negotiate drug prices for its Medicare health program "negotiation with a gun to your head ." Bristol Myers Squibb & Co''s (NYSE: BMY ) Eliquis, Pfizer''s Ibrance, and AbbVie … Full story available on Benzinga.com
AbbVie Inc. (ABBV) to Present at the Goldman Sachs 44th Annual Global Healthcare Conference 2023/06/06 13:07:38 Marijuana Stocks
AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023. Robert A. Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, chief commercial officer and Roopal Thakkar, senior vice president, development and regulatory affairs and chief medical officer, will present at 10:00 a.m. Central time. A live audio webcast of the presentation will be accessible through AbbVie’s Investor Relations website at investors.abbvie.com. An archived edition of the session will be available later that day. About AbbVie AbbVie’s mission is to discover and deliver innovative medicines that solve serious health issues today and address the medical challenges of tomorrow. We strive to have a remarkable impact on people’s lives across several key therapeutic areas: immunology, oncology, neuroscience, eye care, virology and gastroenterology, in addition to products and services across our Allergan Aesthetics portfolio.
AbbVie to Present at the Goldman Sachs 44th Annual Global Healthcare Conference 2023/06/06 12:00:00 PR Newswire
NORTH CHICAGO, Ill., June 6, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Goldman Sachs 44th Annual Global Healthcare Conference on Wednesday, June 14, 2023. Robert A. Michael, vice chairman and president, Jeffrey R. Stewart, executive vice president, chief commercial…
IBM, CVX, or ABBV: Which Dividend Aristocrat Stock is the Most Compelling Pick? 2023/06/06 04:30:17 TipRanks
During these uncertain times, investors seek reliable dividend-paying companies that can generate stable income. Dividend aristocrats are companies…
AbbVie Stock May Be Falling On Humira LOE - But Investors Shouldn''t Panic 2023/06/05 17:00:02 Seeking Alpha
AbbVie''s share price has been slipping as its globally best-selling drug Humira has lost US patent protection. See why ABBV remains a magnet for investor money.
CHINOOK INVESTOR ALERT: Securities Litigation Partner James (Josh) Wilson Encourages Investors Who Suffered Losses Exceeding $50,000 In Chinook To Contact Him Directly To Discuss Their Options 2023/06/03 12:00:00 Kwhen Finance
AbbVie’s Rinvoq for Crohn’s Disease to see rapid uptake by healthcare providers: GlobalData 2023/06/02 06:26:14 Express Pharma
It is expected that the prescribing patterns of Rinvoq by HCPs will follow an ongoing trend by gastroenterologists to be more aggressive when treating CD to slow or prevent the progression of the disease The post AbbVie’s Rinvoq for Crohn’s Disease to see rapid uptake by healthcare providers: GlobalData appeared first on Express Pharma .
AbbVie, Amgen hit 52-week lows as Coherus unveils cheapest Humira version 2023/06/01 18:17:38 Seeking Alpha
AbbVie (ABBV), and Amgen (AMGN) reached 52-week lows Thursday after Coherus BioSciences (CHRS) announced plans to launch the cheapest version of Humira. Read more here.
Why Is AbbVie Stock Trading Down Today? 2023/06/01 18:03:53 Benzinga
AbbVie Inc. (NYSE: Full story available on Benzinga.com
Why AbbVie and Amgen Are Moving Lower Today 2023/06/01 16:50:20 The Motley Fool
An ultra-low-priced biosimilar may negatively impact both biotechs.
AbbVie to Present at the Bank of America Securities Healthcare Conference 2023/05/02 12:00:00 PR Newswire
NORTH CHICAGO, Ill., May 2, 2023 /PRNewswire/ -- AbbVie (NYSE: ABBV) will participate in the Bank of America Securities Healthcare Conference on Tuesday, May 9, 2023. Robert A. Michael, vice chairman and president, Scott Reents, executive vice president, chief financial officer, Jeffrey R….
Vertex Pharmaceuticals Stock Is an Even Better Buy Now Thanks to AbbVie 2023/05/02 09:50:00 The Motley Fool
One big drugmaker''s pain translates into another big drugmaker''s gain.
Check Out What Whales Are Doing With ABBV 2023/05/01 19:16:54 Benzinga
Someone with a lot of money to spend has taken a bullish stance on AbbVie (NYSE: ABBV ). And retail traders should know. We noticed this today when the big position showed up on publicly available options history that we track here at Benzinga. Whether this is an institution or just a wealthy individual, we don''t know. But when something this big happens with ABBV, it often means somebody knows something is about to happen. So how do we know what this whale just did? Today, Benzinga ''s options scanner spotted 15 uncommon options trades for AbbVie. This isn''t normal. The overall sentiment of these big-money traders is split between 66% bullish and 33%, bearish. Out of all of the special … Full story available on Benzinga.com